# US 2023/0406907 A1 · Neutralizing Antibodies that Bind the SARS-COV-2 S Protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0406907 A1
- Document ID: US20230406907A1
- Status: Published application
- Kind: A1
- Application number: 17/923,166
- Filed: 2021-05-05
- Published: 2023-12-21
- Earliest claimed: 2020-05-06
- Assignees: Sorrento Therapeutics, Inc.
- Applicants: Sorrento Therapeutics, Inc.
- Inventors: Heyue Zhou; Xia Cao; Lucy Lu; Ying Yan; Yanliang Zhang; Henry Hongjun Ji; Robert Allen
- Web page: https://patentgrep.com/patent/US20230406907A1

## CPC

- C07K 14/005: from viruses
- A61K 39/42: viral
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- C07K 16/102: Coronaviridae (F)
- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides antigen-binding proteins, such as fully human antibodies, that specifically bind the spike (S) protein of the SARS-CoV-2 coronavirus and uses thereof. In various embodiments, the anti-spike protein antibodies are neutralizing antibodies that prevent binding of the SARS-CoV-2 coronavirus to a target cell expressing the ACE2 protein. Included are anti-spike protein antibodies, antibody fragments, and single-chain antibodies, as well as pharmaceutical compositions that include such antibodies and antibody fragments. Also provided herein are nucleic acids and recombinant expression vectors that encode the anti-spike protein antibodies and antibody fragments disclosed herein and transgenic cells transected with such nucleic acids and expression vectors. Further provided are methods for preparing and using such anti-spike protein antibodies. Methods for using the anti-spike protein antibodies include methods of treating or preventing infection with a coronavirus, such as the SARS-CoV-2 coronavirus, by administering an antibody or antibody fragment as disclosed herein.

## Claims

### Claim 1

An isolated antigen-binding protein that specifically binds the spike (S) protein of SARS-CoV-2, wherein the antigen-binding protein comprises a heavy chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:6 and a light chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:7.

### Claim 2

An isolated antigen-binding protein that specifically binds the S protein of SARS-CoV-2, comprising a heavy chain variable region comprising a heavy chain complementarity determining region (CDR) 1 having the amino acid sequence of SEQ ID NO:8, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:9, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:10, and a light chain variable region comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO:11, a light chain CDR2 having the amino acid sequence of SEQ ID NO:12, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:13.

### Claim 3 (depends on 2)

The isolated antigen-binding protein according to claim 2, wherein the heavy chain variable domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:6 and the light chain variable domain has at least 95% sequence identity to the amino acid sequence of SEQ ID NO:7

### Claim 4 (depends on 2)

The isolated antigen-binding protein according to claim 2, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:6 and the light chain variable region comprises the amino acid sequence of SEQ ID NO:7.

### Claim 5 (depends on 1, 2, 3, 4)

The isolated antigen-binding protein of any one of claims 1-4, wherein the antigen-binding protein binds the S protein of SARS-CoV-2 with a dissociation constant (Kd) of 10−7 M or less.

### Claim 6 (depends on 5)

The isolated antigen-binding protein of claim 5, wherein the antigen-binding protein binds the S protein of SARS-CoV-2 with a Kd of 10−8 M or less.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The isolated antigen-binding protein of any of claims 1-6, wherein the antigen-binding protein is an antibody or antibody fragment.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The isolated antigen-binding protein of any of claims 1-6, wherein the antigen-binding protein is a fully human antibody, comprises a heavy chain variable region and a light chain variable region of a fully human antibody, or comprises an antibody fragment derived from a fully human antibody.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The isolated antigen-binding protein of any of claims 1-8, comprising an IgG antibody, which is optionally an IgG1, IgG2, IgG3, or IgG4 antibody.

### Claim 10 (depends on 9)

The isolated antigen-binding protein of claim 9, comprising an IgG1 or IgG4 antibody.

### Claim 11 (depends on 10)

The isolated antigen-binding protein of claim 10, wherein the IgG1 or IgG4 antibody comprises a mutant Fc region.

### Claim 12 (depends on 11)

The isolated antigen-binding protein of claim 11, wherein the Fc region comprises at least one mutation that decreases antibody-dependent-enhancement (ADE) of infection.

### Claim 13 (depends on 11, 12)

The isolated antigen-binding protein of claim 11 or 12, wherein Fc region comprises one or more mutations selected from N297A, N297Q, N297D, L234A, L235A, L235E, P329A, and P329G.

### Claim 14 (depends on 13)

The isolated antigen-binding protein of claim 13, wherein Fc region comprises the mutations L234A and L235A (LALA), optionally wherein the Fc region comprises the sequence of SEQ ID NO: 14 or 16.

### Claim 15 (depends on 11, 12, 13, 14)

The isolated antigen-binding protein of any one of claims 11-14, wherein the Fc region comprises at least one mutation that increases antibody half-life.

### Claim 16 (depends on 11, 12, 13, 14, 15)

The isolated antigen-binding protein of any one of claims 11-15, wherein Fc region comprises one or more mutations selected from M252Y, T256D, T307Q, T307W, M252Y, S254T, T256E, M428L, and N434S.

### Claim 17 (depends on 16)

The isolated antigen-binding protein of claim 16, wherein Fc region comprises the mutations M252Y, S254T, and T256E (YTE), optionally wherein the Fc region comprises the sequence of SEQ ID NO: 15 or 16.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The isolated antigen-binding protein of any of claims 1-17, wherein the antigen-binding protein is a Fab fragment, a Fab′ fragment, or a F(ab′)2 fragment.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The isolated antigen-binding protein of any of claims 1-17, wherein the antigen-binding protein is a single chain antibody, optionally wherein the single chain antibody is an ScFv.

### Claim 20

The isolated antigen-binding protein of any one of the preceding claims, wherein the antigen-binding protein is a neutralizing antibody or antigen-binding fragment thereof that blocks binding of the SARS-CoV-2 S protein to the ACE2 protein.

### Claim 21 (depends on 20)

The isolated antigen-binding protein of claim 20, wherein the IC50 for blocking of binding of S to the ACE2 protein is 10 nM or less.

### Claim 22 (depends on 21)

The isolated antigen-binding protein of claim 21, wherein the IC50 for blocking of binding of S to the ACE2 protein is 5 nM or less.

### Claim 23

The isolated antigen-binding protein of any one of the preceding claims, wherein the antigen-binding protein is a neutralizing antibody or antigen-binding fragment thereof that blocks SARS-CoV-2 infection of target cells.

### Claim 24 (depends on 23)

The isolated antigen-binding protein of claim 23, wherein the IC50 for blocking infection of target cells by SARS-CoV-2 is 10 nM or less.

### Claim 25 (depends on 24)

The isolated antigen-binding protein of claim 24, wherein the IC50 for blocking infection of target cells by SARS-CoV-2 is 5 nM or less.

### Claim 26

A pharmaceutical composition, comprising the antigen-binding protein of any one of the preceding claims and a pharmaceutically-acceptable excipient.

### Claim 27 (depends on 26)

The pharmaceutical composition of claim 26, wherein the antigen-binding protein is an IgG antibody, a Fab, Fab′ or F(ab′)2 fragment, or a single chain antibody.

### Claim 28 (depends on 27)

The pharmaceutical composition of claim 27, wherein the antigen-binding protein is an IgG antibody.

### Claim 29 (depends on 28)

The pharmaceutical composition of claim 28, wherein the antigen-binding protein is an IgG antibody having an Fc region comprising L234A and L235A mutations.

### Claim 30

A nucleic acid molecule that comprises a nucleic acid sequence encoding a polypeptide comprising a heavy chain variable region having at least 95% identity to SEQ ID NO:6.

### Claim 31 (depends on 30)

The nucleic acid molecule of claim 30, wherein the nucleic acid molecule comprises a vector, wherein the vector comprises a promoter operably linked to the nucleic acid sequence encoding a polypeptide comprising the heavy chain variable region.

### Claim 32

A nucleic acid molecule that comprises a nucleic acid sequence encoding a polypeptide comprising a light chain variable region having at least 95% identity to SEQ ID NO:7.

### Claim 33 (depends on 32)

The nucleic acid molecule of claim 32, wherein the nucleic acid molecule comprises a vector, wherein the vector comprises a promoter operably linked to the nucleic acid sequence encoding a polypeptide comprising the light chain variable region.

### Claim 34

A vector comprising a nucleic acid sequence encoding a heavy chain variable region having at least 95% identity to SEQ ID NO:6 and a nucleic acid sequence encoding a light chain variable region having at least 95% identity to SEQ ID NO:7.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

One or more nucleic acid molecules encoding the antigen-binding protein of any one of claims 1-25.

### Claim 36 (depends on 35)

One or more vectors comprising the one or more nucleic acid molecules of claim 35.

### Claim 37 (depends on 30, 31, 32, 33, 34, 35, 36)

A host cell harboring the nucleic acid molecule or vector of any one of claims 30-36.

### Claim 38 (depends on 35)

A pharmaceutical composition comprising the one or more nucleic acid molecules of claim 35.

### Claim 39 (depends on 37)

A method for preparing a neutralizing antibody or a heavy or light chain thereof, the method comprising: culturing a population of the host cell of claim 37 under conditions suitable for expressing the heavy chain variable region and/or the light chain variable region or the antigen-binding protein.

### Claim 40 (depends on 39)

The method of claim 39, further comprising: recovering from the host cells the expressed heavy chain variable region and/or the light chain variable region or the antigen-binding protein.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

A method for treating a subject having or suspected of having a coronavirus infection, the method comprising: administering to the subject an effective amount of the antigen-binding protein of any one of claims 1-25 or the pharmaceutical composition of any one of claims 26-29.

### Claim 42 (depends on 26, 27, 28, 29)

A method for treating a subject having or suspected of having a coronavirus infection, comprising: administering a pharmaceutical composition of any one of claims 26-29 to the subject, wherein said administration is by pulmonary delivery by inhalation.

### Claim 43 (depends on 42)

The method of claim 42, wherein said pulmonary delivery is by a nebulizer.

### Claim 44 (depends on 26, 27, 28, 29)

A method for treating a subject having or suspected of having a coronavirus infection, comprising: administering a pharmaceutical composition of any one of claims 26-29 to the subject, wherein said administration is by intranasal delivery.

### Claim 45 (depends on 41, 42, 43, 44)

The method of any of claims 41-44, further comprising administering to the subject an anti-viral agent.

### Claim 46 (depends on 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 39-45, wherein the subject has a coronavirus infection.

### Claim 47 (depends on 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 39-45, wherein the coronavirus infection is a SARS-CoV-2 infection.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method for detecting the presence of a coronavirus in a sample, comprising:
a) contacting the sample with the antigen-binding protein of any one of claims 1-25 under conditions suitable to form an antibody-antigen complex, wherein the sample contains a target antigen; and
b) detecting the presence of the antibody-antigen complex.

### Claim 49 (depends on 48)

The method of claim 48, wherein the sample comprises phlegm, saliva, blood, cheek scaping, tissue biopsy, hair or semen.

### Claim 50 (depends on 48, 49)

The method of claim 48 or 49, wherein the antibody-antigen complex is detected using a radioactive, colorimetric, antigenic, enzymatic, a detectable bead (such as a magnetic or electrodense (e.g., gold) bead), biotin, streptavidin or protein A-based mode of detection.

### Claim 51 (depends on 48, 49, 50)

A method for diagnosing a subject suspected of having a coronavirus infection using the method of any one of claims 48-50.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The antigen-binding protein of any one of claims 1-25 for use in the method of any one of claims 42-51.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

Use of the antigen-binding protein of any one of claims 1-25 for the manufacture of a medicament for treating, detecting, or diagnosing according to the method of any one of claims 42-51.
